UroGen Pharma Ownership | Who Owns UroGen Pharma?
UroGen Pharma Ownership Summary
UroGen Pharma is owned by 45.95% institutional investors, 9.18% insiders, and 44.87% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 10.66% of URGN shares. UBS Lux Dgtl Hlth Eq Fd seeding P acc is the top mutual fund, with 2.86% of its assets in UroGen Pharma shares.
URGN Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | UroGen Pharma | 45.95% | 9.18% | 44.87% |
Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Rtw investments, lp | 3.56M | 10.66% | $59.69M |
Adage capital partners gp | 2.93M | 6.79% | $31.18M |
Blackrock | 2.19M | 6.57% | $36.81M |
Cowen and company | 2.10M | 6.29% | $35.23M |
Blackrock funding, inc. /de | 2.47M | 5.72% | $26.28M |
Morgan stanley | 1.84M | 5.51% | $30.85M |
Menora mivtachim | 2.30M | 5.34% | $24.53M |
Toronto dominion bank | 1.75M | 4.06% | $18.63M |
Vestal point capital, lp | 1.63M | 3.78% | $17.36M |
Ubs asset management americas | 1.38M | 3.20% | $14.67M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Rosalind advisors | 870.00K | 4.74% | $9.27M |
Stonepine capital management | 324.32K | 2.79% | $3.45M |
Superstring capital management lp | 301.21K | 2.78% | $3.21M |
Silverarc capital management | 1.12M | 2.61% | $11.93M |
Wildcat capital management | 495.61K | 2.09% | $5.28M |
Dafna capital management | 492.51K | 1.33% | $5.25M |
Vestal point capital, lp | 1.63M | 1.03% | $17.36M |
Cowen and company | 2.10M | 0.97% | $35.23M |
Great point partners | 187.84K | 0.94% | $2.00M |
Rtw investments, lp | 3.56M | 0.92% | $59.69M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Toronto dominion bank | 1.75M | 0.03% | 1.75M |
Morgan stanley | 1.84M | 0.00% | 1.45M |
Nantahala capital management | 1.37M | 0.63% | 1.37M |
Vestal point capital, lp | 1.63M | 1.03% | 1.23M |
Ubs group | 922.70K | 0.00% | 876.92K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Ra capital management | - | - | -3.08M |
Cormorant asset management, lp | 300.00K | 0.18% | -1.25M |
Point72 asset management | 317.11K | 0.01% | -1.19M |
Millennium management | 645.78K | 0.00% | -853.42K |
Adage capital partners gp | 2.93M | 0.05% | -807.65K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Nantahala capital management | 1.37M | 0.63% | 1.37M | $14.61M |
Rosalind advisors | 870.00K | 4.74% | 870.00K | $9.27M |
Cantor fitzgerald, l. p. | 360.00K | 0.08% | 360.00K | $3.79M |
Superstring capital management lp | 301.21K | 2.78% | 301.21K | $3.21M |
Hudson bay capital management lp | 233.32K | 0.01% | 233.32K | $2.48M |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -4.00 |
Systm wealth solutions | -48.00 |
Srs capital advisors | -56.00 |
Bessemer group | -85.00 |
Lindbrook capital | -87.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 101 | -23.48% | 19,804,522 | -43.62% | 45 | 0.69% | 52 | -30.67% | 26 | -13.33% |
Sep 30, 2024 | 132 | 9.09% | 35,128,434 | -8.10% | 81 | 0.76% | 75 | -5.06% | 30 | 50.00% |
Jun 30, 2024 | 120 | 2.56% | 38,225,515 | 40.73% | 114 | 2.03% | 78 | 56.00% | 20 | -45.95% |
Mar 31, 2024 | 117 | 8.33% | 27,162,135 | 26.89% | 75 | 1.71% | 50 | -24.24% | 37 | 85.00% |
Dec 31, 2023 | 108 | 1.89% | 21,406,800 | 20.71% | 66 | 1.16% | 66 | 6.45% | 20 | -9.09% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
UBS Lux Dgtl Hlth Eq Fd seeding P acc | 1.32M | 2.86% | - |
UBS (Lux) Digital Health Equity SB USD | 1.32M | 2.86% | - |
iShares Russell 2000 ETF | 998.29K | 2.17% | 7.28K |
Fidelity Small Cap Index | 375.71K | 0.82% | -7.04K |
International Biotechnology Ord | 303.40K | 0.66% | 106.18K |
State St Russell Sm/Mid Cp® Indx NL Cl C | 262.40K | 0.62% | - |
State St Russell Sm/Mid Cp® Indx SL Cl I | 262.40K | 0.57% | - |
iShares Russell 2000 Growth ETF | 256.98K | 0.56% | -1.22K |
iShares Biotechnology ETF | 223.65K | 0.49% | -2.49K |
MEDICAL BioHealth EUR Acc | 188.91K | 0.45% | -232.79K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jan 31, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $8.46K |
Jan 31, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $21.12K |
Jan 31, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $21.12K |
Jan 31, 2025 | Smith Jason Drew | General Counsel | Sell | $30.82K |
Jan 31, 2025 | Smith Jason Drew | General Counsel | Sell | $37.36K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q4 | - | - |
2024 Q3 | - | 2 |
2024 Q2 | - | 1 |
2024 Q1 | - | 13 |
2023 Q3 | - | 1 |
URGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools